Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) EBITDA Margin (2016 - 2025)

Sonoma Pharmaceuticals has reported EBITDA Margin over the past 16 years, most recently at 14.83% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2122.0% year-over-year to 14.83%; the TTM value through Dec 2025 reached 11.32%, up 2789.0%, while the annual FY2025 figure was 35.76%, 326.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 14.83% at Sonoma Pharmaceuticals, down from 5.87% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 5.87% in Q3 2025 and troughed at 185.63% in Q1 2021.
  • A 5-year average of 40.54% and a median of 27.29% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: crashed -11086bps in 2021 and later skyrocketed 9859bps in 2023.
  • Year by year, EBITDA Margin stood at 34.77% in 2021, then tumbled by -66bps to 57.88% in 2022, then surged by 69bps to 18.13% in 2023, then tumbled by -99bps to 36.05% in 2024, then soared by 59bps to 14.83% in 2025.
  • Business Quant data shows EBITDA Margin for SNOA at 14.83% in Q4 2025, 5.87% in Q3 2025, and 10.83% in Q2 2025.